Phase II Study of Taselisib in PIK3CA -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.

MLA

Krop, Ian E., et al. “Phase II Study of Taselisib in PIK3CA -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.” JCO Precision Oncology, vol. 6, Feb. 2022, p. e2100424. EBSCOhost, https://doi.org/10.1200/PO.21.00424.

APA

Krop, I. E., Jegede, O. A., Grilley-Olson, J. E., Lauring, J. D., Mitchell, E. P., Zwiebel, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Kono, S. A., Ford, J. M., Garcia, A. A., Sui, X. D., Siegel, R. D., Slomovitz, B. M., … Flaherty, K. T. (2022). Phase II Study of Taselisib in PIK3CA -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precision Oncology, 6, e2100424. https://doi.org/10.1200/PO.21.00424

Chicago

Krop, Ian E, Opeyemi A Jegede, Juneko E Grilley-Olson, Josh D Lauring, Edith P Mitchell, James A Zwiebel, Robert J Gray, et al. 2022. “Phase II Study of Taselisib in PIK3CA -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.” JCO Precision Oncology 6 (February): e2100424. doi:10.1200/PO.21.00424.